GSK plc (GSK.L) Wednesday announced positive data from the ZOSTER-049 long-term follow-up phase III trial of its shingles vaccine, Shingrix.
Final data from ZOSTER-049 study showed 79.7 percent vaccine efficacy in adults aged 50 years or more, within the period from year six to year 11 after vaccination. Vaccine efficacy remained high at 82.0 percent at year 11 after initial vaccination.
Further, no new safety concerns were identified during the follow-up period.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.